INCOME STATEMENT (Quarterly GAAP In millions $) |
(Sep 30 2023) III. Quarter |
(Jun 30 2023) II. Quarter |
(Mar 31 2023) I. Quarter |
(Dec 31 2022) IV. Quarter |
(Sep 30 2022) III. Quarter |
Revenue From Contract With Customer Including Assessed Tax |
113.43 |
83.15 |
49.87 |
|
15.38 |
License And Milestone Fees Revenue |
- |
- |
- |
|
- |
Research And Development Revenue |
- |
- |
- |
|
- |
License And Milestone Fees |
- |
- |
- |
|
- |
Non Cash Royalty Revenue Related To Sale Of Future Royalties |
- |
- |
- |
|
- |
Clinical Material Revenue |
- |
- |
- |
|
- |
Total Revenue |
113.43 |
83.15 |
49.87 |
41.17 |
15.38 |
Cost of Revenues |
- |
- |
- |
- |
- |
Gross
Profit |
113.43 |
83.15 |
49.87 |
41.17 |
15.38 |
Selling, Administration, Marketing |
37.74 |
36.36 |
40.02 |
42.07 |
33.62 |
Depriciation & Amortization |
- |
- |
- |
- |
- |
Research and Development Expense |
47.57 |
50.08 |
51.62 |
58.49 |
59.18 |
Restructuring Charges |
- |
- |
- |
- |
- |
Other operatinig exp. /-income |
- |
0.91 |
0.63 |
0.18 |
- |
Unusual Expense /-Income |
- |
- |
- |
- |
- |
Cost Of Goods And Services Sold Operating |
2.16 |
- |
- |
- |
- |
Total operating costs including COS |
87.47 |
87.34 |
92.26 |
100.73 |
92.80 |
Operating income/-loss
|
25.96 |
-4.19 |
-42.39 |
-59.56 |
-77.43 |
Other Deductions / - Income |
Interest expense |
- |
- |
- |
- |
- |
Interest income |
- |
- |
- |
- |
- |
Net interest expense/-income |
- |
- |
- |
- |
- |
Investment Income, Net |
- |
- |
- |
- |
- |
Foreign Currency Transaction (Gain) Loss |
- |
- |
- |
- |
- |
Allowances, Health Care Trust Fund And Other |
- |
- |
- |
- |
- |
Unexpected (Gain) Loss |
- |
- |
- |
- |
- |
Other loss/ -income |
-3.63 |
-0.82 |
-1.38 |
-1.77 |
-0.54 |
Non Cash Interest Expense From Sale Of Future Royalties |
- |
- |
- |
- |
0.87 |
Total costs & expenses |
83.84 |
86.52 |
90.88 |
98.96 |
93.13 |
Income /-loss before income taxes |
29.58 |
-3.37 |
-41.01 |
-57.79 |
-77.76 |
Income taxes expenses/-benefit |
-1.17 |
0.88 |
- |
1.22 |
- |
Income after income taxes |
30.75 |
-4.25 |
-41.01 |
-59.01 |
-77.76 |
Net income/-loss
of other equity |
- |
- |
- |
0.00 |
- |
Income/-loss
from cont. Ops. |
30.75 |
-4.25 |
-41.01 |
-59.01 |
-77.76 |
Accounting change |
- |
- |
- |
- |
- |
Discontinued operations |
- |
- |
- |
- |
- |
Extraordinary items |
- |
- |
- |
- |
- |
Net Income/-loss |
30.75 |
-4.25 |
-41.01 |
-59.01 |
-77.76 |
Noncontrolling interests |
- |
- |
- |
- |
- |
Prefered dividends |
- |
- |
- |
- |
- |
Other |
- |
- |
- |
- |
- |
Income/-loss to shareholder |
30.75 |
-4.25 |
-41.01 |
-59.01 |
-77.76 |
EBIT |
29.58 |
-3.37 |
-41.01 |
-57.79 |
-77.76 |
EBITD |
30.01 |
-2.94 |
-40.57 |
-57.36 |
-77.33 |
EBITDA |
30.01 |
-2.94 |
-40.57 |
-57.36 |
-77.33 |